As Tilray Expands Its Medical Cannabis Business, Should You Buy, Sell, or Hold TLRY Stock?

Tilray’s fiscal year 2025 earnings, released on July 28, reflect steady progress despite strategic challenges. The company achieved net revenue of $821 million, increasing 4% from $789 million the prior year. That figure rises to $834 million when adjusted for constant currency. This revenue growth was partly tempered by a $35 million impact from international permit delays and strategic priorities in Canada, including a $15 million revenue hit from deemphasizing vape products. This helped Tilray preserve h ...